StockIQStockIQ.tech

McKesson Corporation (MCK) Stock Analysis

--

Free AI-powered analysis and research for McKesson Corporation stock

Sector: Healthcare

MCK snapshot

Data as of 3 Nov 2026 close. Updated daily.

Last close
1,002.55 USD (+0.42%)
52-week range
723.68 – 1,030.27
Position in range
91%
1-year change
+22.2%
Market cap (USD)
$116.9B
P/E (trailing)
26.7
RSI (14-day)
63
vs 200-day average
+16.0%
MACD
Below signal line
StockIQ score: 53/100 · Mixed signals

McKesson Corporation scores 53/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 91% of its 52-week range, up 22.2% over the past year. Latest reported figures show a profit margin of 1.1% and revenue growth of +7.7%.

What is driving the score
  • Strong Uptrend: +12
  • MACD Bearish: -8
  • Weak Profit Margin (1.1%): -8
  • Low Liquidity (0.89 Current Ratio): -10
  • Low P/B (-27.21): +5
  • Strong Long-term Uptrend: +8
  • Healthy Momentum (+22.2% over 1 year): +7
  • Low Volume (0.4x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full MCK report

McKesson Corporation (MCK) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze MCK Now β†’

πŸ“° Latest Update

Wall Street Bulls Look Optimistic About McKesson (MCK): Should You Buy?

Analysts are optimistic about McKesson (MCK), with an average brokerage recommendation (ABR) of 1.47, indicating a strong buy sentiment from 76.5% of the 17 brokerage firms surveyed. However, the article cautions that brokerage recommendations may be overly optimistic due to vested interests, suggesting that investors should also consider the Zacks Rank, which currently assigns McKesson a rank of #3 (Hold) based on unchanged earnings estimates. This indicates a need for caution despite the favorable ABR.

Read full article β†’

History

People also watch

REGN
Regeneron Pharmaceuticals Inc.
--
VRTX
Vertex Pharmaceuticals Inc.
--
ZTS
Zoetis Inc.
--
MIRM
Mirum Pharmaceuticals, Inc.
--
ADPT
Adaptive Biotechnologies Corporation
--